Julie J. Paik

Julie J. Paik

Rheumatology

4940 Eastern Avenue
Bayview Medical Offices, Level 01 (G), Clinic 5
Baltimore, MD 21224

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 151 publications

The current clinical trial landscape in idiopathic inflammatory myopathies.

The current clinical trial landscape in idiopathic inflammatory myopathies.

Journal: Current opinion in rheumatology

Published: August 26, 2026

A Phase 3 Trial of Brepocitinib in Dermatomyositis.

A Phase 3 Trial of Brepocitinib in Dermatomyositis.

Journal: The New England journal of medicine

Published: March 30, 2026

A Phase 3 Trial of Brepocitinib in Dermatomyositis.

A Phase 3 Trial of Brepocitinib in Dermatomyositis.

Journal: The New England journal of medicine

Published: March 30, 2026

Standardized Interoperable Data Collection for Myositis Research: Developing Expert Consensus on Common Data Elements for Myositis Outcome Measures.

Standardized Interoperable Data Collection for Myositis Research: Developing Expert Consensus on Common Data Elements for Myositis Outcome Measures.

Journal: Arthritis care & research

Published: December 08, 2025

Standardized Interoperable Data Collection for Myositis Research: Developing Expert Consensus on Common Data Elements for Myositis Outcome Measures.

Standardized Interoperable Data Collection for Myositis Research: Developing Expert Consensus on Common Data Elements for Myositis Outcome Measures.

Journal: Arthritis care & research

Published: December 08, 2025

Quantitative Muscle Magnetic Resonance Imaging Demonstrates Resolution of Muscle Edema in Refractory Dermatomyositis: A Post Hoc Analysis of a Proof-of-Concept Clinical Trial of Tofacitinib.

Quantitative Muscle Magnetic Resonance Imaging Demonstrates Resolution of Muscle Edema in Refractory Dermatomyositis: A Post Hoc Analysis of a Proof-of-Concept Clinical Trial of Tofacitinib.

Journal: ACR open rheumatology

Published: December 03, 2025

Validity and reliability of hand-held dynamometry for proximal strength assessment in systemic sclerosis-associated myopathy.

Validity and reliability of hand-held dynamometry for proximal strength assessment in systemic sclerosis-associated myopathy.

Journal: Seminars in arthritis and rheumatism

Published: November 24, 2025

Discordance Between Patient and Physician Global Assessments in Early Systemic Sclerosis.

Discordance Between Patient and Physician Global Assessments in Early Systemic Sclerosis.

Journal: Arthritis care & research

Published: November 21, 2025

Fibrosing myopathy in systemic sclerosis: Treatment response and clinical outcomes in a distinct subset.

Fibrosing myopathy in systemic sclerosis: Treatment response and clinical outcomes in a distinct subset.

Journal: Seminars in arthritis and rheumatism

Published: November 10, 2025

Myositis in 2025: Defining Subtypes, Closing Gaps, and Shaping the Future.

Myositis in 2025: Defining Subtypes, Closing Gaps, and Shaping the Future.

Journal: Rheumatic diseases clinics of North America

Published: October 29, 2025

The Spectrum of Myocardial Disease in Idiopathic Inflammatory Myopathies.

The Spectrum of Myocardial Disease in Idiopathic Inflammatory Myopathies.

Journal: Rheumatic diseases clinics of North America

Published: October 29, 2025

Recurrent and new primary cancer risk in adult patients with idiopathic inflammatory myositis and a history of malignancy.

Recurrent and new primary cancer risk in adult patients with idiopathic inflammatory myositis and a history of malignancy.

Journal: Clinical and experimental rheumatology

Published: September 04, 2025

Showing 1-12 of 151

Last Updated: 09/26/2026